DSL(SH:603233) Xin Lang Cai Jing·2025-09-22 06:05Company Overview - Dazhonglin Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, established on February 12, 1999, and listed on July 31, 2017 [2] - The company's main business includes retail of traditional Chinese and Western medicines, health products, medical devices, and other goods, with revenue composition as follows: Western and Chinese medicines 76.88%, non-pharmaceuticals 10.49%, Chinese medicinal materials 9.75%, and others 2.88% [2] Financial Performance - For the first half of 2025, Dazhonglin achieved operating revenue of 13.523 billion yuan, a year-on-year increase of 1.33%, and a net profit attributable to shareholders of 798 million yuan, a year-on-year increase of 21.38% [2] - Since its A-share listing, Dazhonglin has distributed a total of 3.355 billion yuan in dividends, with 1.624 billion yuan distributed in the last three years [3] Stock Performance - As of September 22, Dazhonglin's stock price decreased by 2.02% to 16.99 yuan per share, with a total market capitalization of 19.349 billion yuan [1] - Year-to-date, the stock price has increased by 15.19%, with a decline of 1.74% over the last five trading days and a 0.70% decline over the last 20 days [2] - The stock has seen a 4.23% increase over the last 60 days [2] Shareholder Information - As of June 30, 2025, the number of shareholders is 31,500, a decrease of 10.07% from the previous period, with an average of 36,097 circulating shares per person, an increase of 11.20% [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 90.448 million shares, an increase of 12.4318 million shares from the previous period [3] Market Activity - On September 22, the net outflow of main funds was 3.2502 million yuan, with large orders buying 4.3386 million yuan (5.52% of total) and selling 7.5887 million yuan (9.66% of total) [1]